Nearly one out of every seven households in the United States is affected by a neurological disorder like Alzheimer, Parkinson or Huntington disease. Yet these devastating diseases that cause the progressive loss of memory, mobility or both have no cure, and some are impossible to even predict.
HudsonAlpha understands that all neurodegenerative diseases are interconnected—as interconnected as the nervous system itself. Finding answers about one disease may lead to answers about many of them. That’s why we established the Memory and Mobility (M&M) Fund. This fund will support new projects and continue existing work in a variety of neurodegenerative diseases that impact so many people in our country and around the world.
Impacting Alzheimer Disease Campaign
Identifying New Causes
As a leader in the genomic science community, HudsonAlpha Institute for Biotechnology has a rare opportunity to access a large set of samples for Alzheimer research. We are sequencing the whole genomes of more than 2,200 individuals to help us learn more about the genetic causes of Alzheimer disease and related disorders. Using a collaborative approach, we will share our findings with the entire research community, which will increase the power to identify new genes with confidence. This will aid in developing new medicines that will benefit patients.
Early detection of Alzheimer disease is very important in improving treatment outcomes. At HudsonAlpha, we will use our expertise in immunogenomics (applying genomic technologies to better understand the immune system) to help identify the earliest onset of Alzheimer disease. By analyzing the immune response found in the blood of Alzheimer patients, we can generate a picture of health – something we call the immune repertoire – that may allow clinicians to detect disease long before symptoms appear or are recognized, making early drug therapies more effective. This new diagnostic test will offer patients alternatives to the current more expensive tests.
Discovering New Therapeutic Approaches
All genes have an “on/off ” switch. Controlling how genes are turned on and off is an important process called gene regulation. Using knowledge from our successful program with another neurological disease, we will explore the potential for gene regulation with Alzheimer disease. We are doing this by identifying all the “on/off ” switches for known Alzheimer disease genes. By learning how to turn off the abnormal genes responsible for Alzheimer disease in some people, our research may lead to completely new therapeutic approaches that could significantly slow or stop progression of Alzheimer disease.
Please join us in making a difference. Contribute to the Impacting Alzheimer Disease project. We are close…but we aren’t there yet. To explore the possibilities of finding cures and treatments for Alzheimer disease, we need your help to close the gap and raise an additional $1.5M.
More than five million Americans have Alzheimer disease and that number continues to climb. By 2050, the number could rise as high as 16 million.
Today, genomic research is opening doors that are leading to new discoveries and hope for a better future. We can’t do it without you. Through genomic science and your support, we can make a difference together.
To view the complete project scope, download our information guides:
For more information, please contact Elizabeth Herrin at 256-327-0442 or email@example.com.
The HudsonAlpha Foundation, a 501(c)(3) nonprofit organization, is the supporting entity for the HudsonAlpha Institute for Biotechnology. Tax-deductible contributions to the foundation are for the sole purpose of advancing the mission of the HudsonAlpha Institute for Biotechnology.
Tax identification #27-2320591